钱海，博士，研究员，博士生导师。
2001年毕业于山东大学药学院药学专业，2007获中国药科大学药物化学专业博士学位。现任职药物科学研究院新药研究中心，主要从事降血糖、抗肿瘤、逆转肿瘤多药耐药等方向的小分子及多肽药物的设计合成、生物活性及构效关系研究。2010年获第13届中国药学会-施维雅青年药物化学奖。江苏省“333高层次人才培养工程”第三层次培养对象。
研究方向：新药分子设计与合成研究
科研项目：
主持国家自然基金面上项目、教育部科学技术研究重点项目、教育部博士点研究项目和江苏省自然科学基金青年项目各一项；参与国家自然基金面上项目二项、国家“十一五”新药创制重大专项临床前和候选药物各一项；承担企业横向课题多项。现在研项目：
1.苦瓜多肽类似物的分子构建、降糖活性和作用机制研究国家自然科学基金面上项目，81273376， 2013/01-2016/12，主持
2.胰高血糖素样肽-1—香豆素类缀合长效衍生物的合成、生物活性及作用机制研究国家自然科学基金面上项目，81172932， 2012/01-2015/12，参与
3.新型肿瘤多药耐药逆转剂HZ08与P-糖蛋白结合模式及转运机制研究国家自然科学基金面上项目，81173088，2012/01-2015/12，参与
4.苦瓜多肽类似物的分子构建、降糖活性和作用机制研究江苏省自然科学基金青年项目，BK2012356， 2012/07-2015/05，主持
5.复星医药技术创新战略联盟项目新药创制重大专项，2010ZX09401-401， 2010/01-2013/12，参与
主要论文：
已发表SCI论文40余篇。参与申请中国专利 29项，国际专利2项，已授权5项。近期代表论文：
1.Xin Deng, Qianqian Qiu, Baowei Yang, Xuekun Wang, Wenlong Huang* , Hai Qian*. Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. European Journal of Medicinal Chemistry, 2015, 89(1), 540–548.
2.Xuekun Wang, Tianxiao Zhao, Baowei Yang, Zheng Li, Jian Cui, Yuxuan Dai, Qianqian Qiu,Hao Qiang, Wenlong Huang*, Hai Qian*. Synthesis and biological evaluation of Phenoxyacetic acid Derivatives as Novel Free Fatty Acid Receptor 1 Agonists. Bioorganic & Medicinal Chemistry, 2015，23 (1), 132–140.
3.Lei Jiao, Qianqian Qiu, Baomin Liu, Tianxiao Zhao, Wenlong Huang*, Hai Qian*. Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents. Bioorganic & Medicinal Chemistry , 2014, 22 (24) 6857–6866.
4.Jing Han, Lidan Sun, Xun Huang, Zheng Li, Chenyu Zhang, Hai Qian* and Wenlong Huang*. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. British Journal of Pharmacology，2014，171 (23) 5252–5264.
5. Baowei Yang, Yicheng Mei, Xuekun Wang, Xin Deng, Hai Qian*, Wenlong Huang*. Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents. European Journal of Medicinal Chemistry, 2014, (73),105-111.
6. Baomin Liu, Qianqian Qiu, Tianxiao Zhao,Lei Jiao, Jianyu Hou, Yunman Li, Hai Qian* and Wenlong Huang* Discovery of Novel P-Glycoprotein-Mediated Multidrug Resistance Inhibitors Bearing Triazole Core via Click Chemistry. Chem Biol Drug Des, 2014, 84(2), 182–191.
7. Jing Han, Lidan Sun, Yingying Chu, Zheng Li, Dandan Huang, Xiaoyun Zhu, Hai Qian*, Wenlong Huang*. Design, Synthesis and Biological activity studies of Novel Dicoumarin-Glucagon-Like Peptide-1 Conjugates. Journal of Medicinal Chemistry, 2013，56(24), 9955-9968.
8. Jing Han, Xun Huang, Lidan Sun, Zheng Li, Hai Qian*, Wenlong Huang*, Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochemical Pharmacology, 2013, 86(2), 297-308.
9. Baowei Yang, Wei Chen, Jing Jin, Yicheng Mei, Xuekun Wang, Hong Chen, Sijia Yan, Meng Ru, Guolong Gu, Xin Deng, Hai Qian* and Wenlong Huang*，Evaluation of Hypoglycemic and Antioxidative Effects of Synthesized Peptide MC62. Chem Biol Drug Des, 2013, 82(1), 99–105.
10. Chunlei Tang, Shu Chen, Hai Qian* and Wenlong Huang*. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology, 2012, 135(2), 112–124.
联系方式：
南京市童家巷24号，中国药科大学，科研大楼1709室，邮编：210009
电话：025-83271302
E-mail：qianhai24@163.com or qianhai24@cpu.edu.cn